Business Context and Reporting Period
This Form 8-K, filed on April 28, 2020, by resTORbio, Inc. (the "Registrant"), announces the entry into a definitive Agreement and Plan of Merger with Adicet Bio, Inc. ("Adicet"). Under the agreement, Adicet will merge with a wholly-owned subsidiary of resTORbio, with Adicet surviving as a wholly-owned subsidiary of resTORbio. The transaction is structured as a tax-free reorganization. The combined company intends to change its name to "Adicet Bio, Inc." and effect a reverse stock split of resTORbio common stock.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the merger rather than historical operating results. Key metrics include:
- Ownership Structure: Post-merger, former Adicet securityholders are expected to own approximately 75% of the combined company on a fully-diluted basis, while former resTORbio securityholders are expected to own approximately 25%.
- Termination Fees: The agreement stipulates a termination fee of $6,100,000 payable by either party under specified circumstances, plus reimbursement of out-of-pocket fees and expenses up to $1,000,000.
- Funding Commitment: Adicet investors have committed to fund up to $15,000,000 into an escrow account to subscribe for shares in a concurrent private placement. This is part of a target "Qualified Financing" of at least $30,000,000 in aggregate gross proceeds.
- Contingent Value Rights (CVRs): Existing resTORbio shareholders will receive CVRs entitling them to net proceeds from the commercialization of resTORbio's RTB101 candidate for a COVID-19 indication, with clinical data expected by Q1 2021.
The filing text does not provide specific revenue, profit, cash flow, or debt figures for either company.
Material Changes and Agreements
The primary material change is the execution of the Merger Agreement, which includes:
- Stockholder Support: Agreements have been signed with resTORbio stockholders owning approximately 24% of outstanding shares and Adicet stockholders owning approximately 96% of outstanding stock to vote in favor of the merger.
- Lock-Up Agreements: Key stockholders of both companies (representing ~94% of Adicet and ~24% of resTORbio) have agreed to a 180-day lock-up on the sale or transfer of shares following the closing.
- Board Composition: The post-merger board will consist of seven directors: five designated by Adicet, one by resTORbio, and the resTORbio CEO.
- No-Shop Provision: Both parties are restricted from soliciting alternative acquisition proposals, subject to fiduciary out exceptions.
Guidance, Outlook, and Risks
Management commentary focuses on the strategic rationale of combining Adicet's CAR-T cell therapy platform with resTORbio's assets. The filing includes extensive forward-looking statements regarding the completion of the merger, clinical trial timelines, and capital sufficiency.
Key Risks and Contingencies:
- Closing Conditions: The merger is subject to stockholder approvals from both companies, the effectiveness of a Form S-4 registration statement, and the satisfaction of other customary conditions.
- Financing Risk: The $15 million funding commitment is contingent on a Qualified Financing of at least $30 million occurring within 12 months of the closing; otherwise, funds are returned to investors.
- CVR Uncertainty: There is no assurance that the CVRs will result in any value to resTORbio shareholders if RTB101 is not successfully commercialized.
- Regulatory and Clinical Risks: Risks include the timing of clinical trials, regulatory approvals, and the impact of the COVID-19 pandemic on operations.
Important Facts for Investor Verification
- Verify the final exchange ratio and the specific reverse stock split ratio to be determined by the companies.
- Confirm the status of the Form S-4 filing and the scheduled dates for stockholder meetings for both resTORbio and Adicet.
- Monitor the progress of the "Qualified Financing" to ensure the $30 million threshold is met to secure the $15 million investor commitment.
- Review the terms of the CVR Agreement regarding the specific milestones and payout structure for the RTB101 COVID-19 candidate.
- Assess the potential for termination fees ($6.1 million) if the deal fails to close due to stockholder rejection or regulatory issues.